Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 04, 2026 07:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and...
February 19, 2026 07:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If...
September 17, 2025 07:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation

FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a...
October 22, 2013 12:44 ET | Source: abas-USA

abas-USA Announces New On-Site Training Facility

STERLING, VA--(Marketwired - Oct 22, 2013) - abas-USA is pleased to announce they will be moving and expanding their East Coast headquarters in November. The new facility will accommodate future...